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Fluorescent VEGF-A isoforms have been evaluated
for their ability to discriminate between VEGFR2
and NRP1 in real-time ligand binding studies in live
cells using BRET. To enable this, we synthesized
single-site (N-terminal cysteine) labeled versions of
VEGF165a, VEGF165b, and VEGF121a. These were
used in combination with N-terminal NanoLuc-
tagged VEGFR2 or NRP1 to evaluate the selectivity
of VEGF isoforms for these two membrane proteins.
All fluorescent VEGF-A isoforms displayed high
affinity for VEGFR2. Only VEGF165a-TMR bound to
NanoLuc-NRP1 with a similar high affinity (4.4 nM).
Competition NRP1 binding experiments yielded a
rank order of potency of VEGF165a > VEGF189a >
VEGF145a. VEGF165b, VEGF-Ax, VEGF121a, and
VEGF111a were unable to bind to NRP1. There were
marked differences in the kinetic binding profiles of
VEGF165a-TMR for NRP1 and VEGFR2. These data
emphasize the importance of the kinetic aspects of
ligand binding to VEGFR2 and its co-receptors in
the dynamics of VEGF signaling.
INTRODUCTION
Angiogenesis, the growth of new blood vessels from pre-existing
vasculature, is critical in both physiology and pathology for main-
taining an adequate supply of oxygen and nutrients (Chung and
Ferrara, 2011). Vascular endothelial growth factor A (VEGF-A) is
an essential mediator of both angiogenesis and vascular perme-
ability that signals via its cognate receptor VEGF receptor 2
(VEGFR2) (Koch et al., 2011; Shibuya, 2011). VEGF binds to
VEGFR2 at the extracellular immunoglobulin (Ig)-like domains 2
and 3 (D2/D3) of the receptor (Ruch et al., 2007). VEGF binding
stimulates receptor dimerization and initiates conformational
changes across the VEGFR2 dimer interface that result in
auto- and transphosphorylation of intracellular tyrosine residuesCell Chemical Biology 25, 1–11, O
This is an open access article und(Cunningham et al., 1997). Subsequent recruitment of adaptor
proteins and activation of downstream signaling cascades leads
to cell proliferation, migration, and survival (Koch et al., 2011).
VEGFR2 is overexpressed in many solid tumors and leads to
activation of pro-angiogenic signaling, which promotes tumori-
genesis. As a consequence, a number of anti-angiogenic thera-
peutics have been targeted at the VEGF/VEGFR2 axis (Ferrara
and Adamis, 2016).
VEGFR2 signaling is selectively enhanced by its co-receptor
neuropilin-1 (NRP1), a transmembrane glycoprotein that lacks
kinase activity and whose upregulation in malignant tumors is
correlated to aggressive cancer phenotypes (Jubb et al., 2012;
Goel and Mercurio, 2013; Lee et al., 2014). NRP1 is a multifac-
eted co-receptor that can also bind structurally and functionally
unrelated class 3 semaphorins (Djordjevic and Driscoll, 2013;
Guo and Vander Kooi, 2015). However, its functional role in
vessel development is evident from the severe cardiovascular
abnormalities exhibited in Nrp1 knockout mice (Kitsukawa
et al., 1997; Kawasaki et al., 1999; Gu et al., 2003). NRP1 selec-
tively potentiates VEGFR2-mediated endothelial cell motility and
vascular permeability without promoting proliferation, driving
arterial vessel development in vivo (Chittenden et al., 2006;
Fantin et al., 2011; Lanahan et al., 2013). While it lacks kinase
activity, NRP1 has a short cytoplasmic tail containing a serine-
glutamate-alanine motif that interacts with PDZ domain-contain-
ing synectin (Cai and Reed, 1999;Wang et al., 2006; Prahst et al.,
2008), through which NRP1maymodulate VEGFR2 trafficking or
expression (Ballmer-Hofer et al., 2011). VEGF interacts with
NRP1 via a C-terminal arginine residue, whereas N-terminal res-
idues on VEGF are responsible for VEGFR2 binding (Djordjevic
and Driscoll, 2013; Guo and Vander Kooi, 2015).
VEGF is an anti-parallel disulfide-linked homodimer with multi-
ple endogenous isoformsresulting fromalternativemRNAsplicing
or encoded by separate genes that each elicit different signaling
outcomes (Woolard et al., 2009). Alternative splicing of the
VEGF-A gene (Vegfa) results in isoforms of varying lengths that
include the prototypical pro-angiogenic isoform VEGF165a and a
freely diffusible VEGF121a isoform lacking interactions with hepa-
rin (Harper and Bates, 2008). Isoforms with a carboxy terminus
substituting CDKPRR for SLTRKD, including VEGF165b and the
more recently identified VEGF-Ax, have reported anti-angiogenicctober 18, 2018 ª 2018 The Author(s). Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)
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warappa et al., 2014). Distinct signaling outcomes downstream of
VEGFR2 have been suggested to result from different abilities of
distinct VEGF isoforms to bind to NRP1 (Simons et al., 2016;
Peach et al., 2018). Despite existing anti-cancer therapeutics tar-
geting VEGF and its known modulation by NRP1, there is limited
quantitative information on the binding characteristics of specific
isoforms at full-length VEGFR2 and NRP1 in living cells.
Significant advances in our understanding of ligand binding to
G-protein-coupled receptors (GPCRs), and more recently RTKs,
have resulted from the development of fluorescent ligand tech-
nologies that use bioluminescence resonance energy transfer
(BRET) (Stoddart et al., 2015, 2018). NanoBRET is a proximity-
based assay that can quantify interactions between a fluores-
cent ligand and a receptor fused at its N terminus to a small,
bright nanoluciferase (NanoLuc) (Machleidt et al., 2015; Stoddart
et al., 2015; Kilpatrick et al., 2017). Having developed a tech-
nique to stoichiometrically label VEGF165a with the red-shifted
fluorophore tetramethylrhodamine (TMR) (Kilpatrick et al.,
2017), we synthesized fluorescent variants of ‘‘anti-angiogenic’’
VEGF165b and freely diffusible VEGF121a to probe their pharma-
cology at full-length VEGFR2 and its co-receptor NRP1 in living
cells at 37C. We report here the binding affinities and real-
time binding kinetics of VEGF-A isoforms to NanoLuc-tagged
VEGFR2 and NRP1. We also demonstrate that fluorescent ana-
logs of VEGF165b and VEGF121a can be used to selectively bind
to VEGFR2 but not NRP1 in living cells.
RESULTS
Generation and Characterization of Stoichiometrically
Labeled VEGF165b-TMR and VEGF121a-TMR
Synthesis and purification of fluorescent VEGF-A isoforms
VEGF165b and VEGF121a (Figure 1A) labeled at a single N-termi-
nal cysteine residue with 6-TMR-PEG-CBT were prepared as
described by Kilpatrick et al. (2017). In brief, VEGF isoforms
were expressed as secreted N-terminal HaloTag fusions. The
linker connecting HaloTag and the VEGF isoforms contained a
modified tobacco etch virus recognition site (EDLYFQC), which
upon proteolytic cleavage released a VEGF isoform with anFigure 1. Functional Characterization of VEGF165b-TMR and VEGF121a
(A) Schematic illustrating exons present in different VEGF-A isoforms following
through (PTR) in VEGF-Ax.
(B and C) NFAT production in HEK293T cells stably expressing wild-type VEGFR
identically to the fluorescent analog (B), or VEGF121a-TMR or unlabeled equivale
wells) expressed as a percentage of the response to 10 nM VEGF165a measured
(D and E) VEGFR2 phosphorylation in HEK293T cells stably expressing NanoLuc-V
VEGF121a (E). Data are presented for VEGF165b or VEGF121a obtained from a c
(Analogue), or for the fluorescent TMR-labeled variants of each VEGF-A isoform.
and stimulated in its presence. Cells were fixed (3% paraformaldehyde [PFA]/P
incubated with an antibody specific for phosphorylated tyrosine 1212, and nuclei s
(203 objective) and quantified using a granularity algorithm (MetaXpress, Molecu
antibody only) and expressed as a percentage normalized to cediranib-treated
periments. Statistical analysis performed using a one-way ANOVA and Sidak’s m
(F and G) Comparison of the extent of HUVEC proliferation in response to stimula
isoforms. Following serum deprivation, HUVECs were stimulated in duplicate well
PBS and nuclei stained with H33342. Cells were imaged using an IX Micro widefie
(MetaXpress, Molecular Devices). Data are expressed as a percentage of the r
experiments. Statistical analyses were performed using a one-way ANOVA and
See also Figures S1 and S2; Tables S1 and S2.N-terminal cysteine residue that can be specifically labeled via
2-cyanobenzothiazole (CBT) condensation.
Labeling specificity of VEGF165b-TMR (Figure S1) and
VEGF121a-TMR (Figure S2) were determined by liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) analysis of
labeled and unlabeled VEGF isoforms that were digested with
multiple proteases as described previously for VEGF165a-TMR
(Kilpatrick et al., 2017). This analysis indicated highly efficient
and selective labeling of the N-terminal cysteine residue of
each VEGF isoform (Figures S1 and S2). 6-TMR-PEG-CBT
chemical modification (817 Da) was identified exclusively on
the N-terminal cysteine residue of each VEGF isoform at 97%
(VEGF165b-TMR) and 94%–99% (VEGF121a-TMR) labeling effi-
ciency (Tables S1 and S2). We did not observe non-specific la-
beling of any of the other cysteine residues present in either
VEGF165b-TMR or VEGF121a-TMR. Fluorescence SDS-PAGE
analysis of the purified VEGF165b-TMR and VEGF121a-TMR iso-
forms in the presence or absence of 100mMDTT confirmed that,
in non-reducing conditions, both VEGF isoforms were largely
present as homodimers (Figures S1 and S2). Deglycosylation
by PNGase provided evidence that the purified VEGF165b-TMR
was glycosylated (Figure S1). However, for VEGF121a-TMR,
treatment with PNGase strongly suggested that it was present
in both glycosylated and non-glycosylated forms under normal
conditions (Figure S2). To confirm the concentrations of
VEGF165b-TMR and VEGF121a-TMR (and their dimeric nature),
we also undertook fluorescence correlation spectroscopy
studies in the presence and absence of 10mMDTT as described
by Kilpatrick et al. (2017) (Figures S1 and S2).
Agonist Activity of Fluorescent VEGF Isoforms in
HEK293 Cells and HUVECs
To determine whether the N-terminal TMR labeling of VEGF165b
and VEGF121a influenced their VEGFR2 agonist activity, we used
acalcium-basednuclear factorof activatedTcells (NFAT) reporter
gene assay (Carter et al., 2015) to measure signaling downstream
of wild-type VEGFR2 expressed in HEK293T cells lacking
VEGFR1 or NRP1 (Figure S3). Figure 1 shows the agonist activity
of VEGF165b-TMR (Figure 1B) and VEGF121a-TMR (Figure 1C)
compared with the agonist actions of equivalent unlabeled-TMR Activities
alternative mRNA splicing, including the region from post-translational read-
2 in response to 5 hr stimulation with VEGF165b-TMR or VEGF165b prepared
nt VEGF121a (C). Data are mean ± SEM (5 independent experiments, duplicate
in the same experiment.
EGFR2 in response to 20min stimulation with 30 nMunlabeled VEGF165b (D) or
ommercial source (R&D Systems) or prepared identically to the TMR analogs
As a negative control, cells were pre-incubated with 1 mM cediranib for 30 min
BS), permeabilized (0.025% Triton-X-PBS), blocked for non-specific binding,
tained with H33342. Cells were imaged using an IXMicro widefield platereader
lar Devices). Data were baseline corrected for non-specific binding (secondary
wells (0%) and response to 30 nM VEGF165a (100%) from 5 independent ex-
ultiple comparisons showed no significance.
tion with VEGF165b or VEGF165b-TMR (F) and VEGF121a or VEGF121a-TMR (G)
s for 48 hr with 0.3, 3, or 30 nM ligand (37C/5%CO2), then fixed using 3%PFA/
ld platereader (43 objective) with nuclei counted using a granularity algorithm
esponse to 3 nM VEGF165a and represent mean ± SEM from 6 independent
Sidak’s multiple comparisons: *p < 0.05.
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rescent variant. Each ligand evoked a submaximal response
compared with the response obtained with 10 nM VEGF165a (Fig-
ures 1B and 1C), consistent with previous work with unlabeled
VEGF165b and VEGF121a (Carter et al., 2015; Kilpatrick et al.,
2017). However, a comparison of the EC50 values of VEGF165b-
TMR and VEGF121a-TMR indicated that the fluorescent ligands
had EC50 values that were an order of magnitude higher than
their unlabeled counterparts (VEGF165b-TMR pEC50 = 8.16 ±
0.11 versus VEGF165b pEC50 = 9.16 ± 0.09; VEGF121a-TMR
pEC50 = 8.57 ± 0.07 versus VEGF121a pEC50 = 9.51 ± 0.09; n = 5
in each case). However, in each case the TMR-labeled VEGF iso-
form produced amaximum response similar to that obtainedwith
the unlabeled VEGF165b or VEGF121a (Figures 1B and 1C).
Although untransfected HEK293T cells did show some low-level
expression of endogenous VEGFR2 (Figure S3), neither untrans-
fected nor NanoLuc-NRP1-expressing cells produced a measur-
able NFAT signal in response to VEGF165a (data not shown).
The agonist effect of the two fluorescent ligandswas also eval-
uated for pY1212 phosphorylation of VEGFR2 using a phospho-
specific antibody (Figures 1C and 1D). At 30 nM, both ligands
were able to stimulate pY1212 phosphorylation to the same
extent as the equivalent unlabeled versions of VEGF165b and
VEGF121a (Figures 1C and 1D).
Finally, we also investigated agonist activity of these VEGF-A
isoforms in human umbilical vein endothelial cells (HUVECs)
that endogenously express both VEGFR2 and NRP1 (Figures
S3, 1C, and 1D). Immunolabeling of HUVECs showed a minimal
presence of endogenous VEGFR1 (Figure S3). Both unlabeled
isoforms stimulated a concentration-dependent increase in
HUVECcell proliferation (Figures 1Eand1F). VEGF165bproduced
a maximum response that was only circa 60% of that obtained
with 3 nM VEGF165a (Figure 1E). In contrast, VEGF121a produced
a response similar to that obtained with VEGF165a (Figure 1F).
Both fluorescent ligands, however, evoked much lower maximal
responses (30% for VEGF165b-TMR; 40% for VEGF121a-TMR)
than those obtained with their unlabeled counterparts (Figures
1E and 1F), indicative of partial agonist activity. In keeping with
this, the EC50 values of the fluorescent isoforms for HUVEC cell
proliferation were, however, very similar to the unlabeled
VEGF165b and VEGF121a (Figures 1E and 1F). This contrasted
markedly with the full agonist response determined previously
with VEGF165a-TMR in HUVECs (Kilpatrick et al., 2017).
Binding of VEGF165a-TMR, VEGF165b-TMR, and
VEGF121a-TMR to VEGFR2
Initial imaging studies were undertaken to monitor the spatial as-
pects of VEGF isoform binding to HaloTag-labeled VEGFR2 ex-
pressed in HEK293T cells (labeled with membrane-impermeant
HaloTag-AlexaFluor488 substrate; Figure 2). Under basal condi-
tions, VEGFR2 was located on both the cell membrane and
within intracellular sites (indicative of constitutive internalization;
Kilpatrick et al., 2017; Figure 2). Following 60-min stimulation
with 10 nM VEGF165a-TMR (Kilpatrick et al., 2017), VEGF165b-
TMR, or VEGF121a-TMR, there was a clear co-localization with
HaloTag-VEGFR2 at both the cell membrane and increased
internalized receptor (Figure 2).
NanoBRET was also used to quantify the real-time binding of
the three fluorescent VEGF-A isoforms to NanoLuc-tagged4 Cell Chemical Biology 25, 1–11, October 18, 2018VEGFR2 expressed in living HEK293T cells at 37C. The assay
is based on the close proximity (<10 nm) required for biolumines-
cence energy transfer between the fluorophore of a receptor-
bound fluorescent ligand (BRET acceptor) and the N-terminal
NanoLuc (BRET donor) of the receptor. Saturable binding
of VEGF165a-TMR, VEGF165b-TMR, and VEGF121a-TMR to
NanoLuc-VEGFR2 was clearly demonstrated, and this was
largely prevented in the presence of 100 nM unlabeled compet-
itor (Figures 3A–3C). Derived equilibrium binding constants re-
vealed that each isoform bound with nanomolar affinity with a
rank order VEGF165a-TMR > VEGF121a-TMR > VEGF165b-TMR
(Table 1). Real-time binding kinetics measured every 30 s at
37C showed VEGFR2 binding peaked within 20 min for each
VEGF-TMR isoform (Figures3D–3F). Kinetic binding experiments
were conducted with five separate concentrations of VEGF-TMR
isoform, which enabled a global fit of the data to provide esti-
mates for kon and koff for each fluorescent ligand. These data
showed that VEGF165a-TMR had a faster kon than VEGF121a-
TMR and VEGF165b-TMR, but each isoform had similar koff rates
(Table 1). The ratio of koff/kon also provided an estimate of the
kinetically derived KD values, which were very similar to those
obtained from equilibrium measurements (Table 1).
To gain some insight into whether NanoLuc-VEGFR2 or
HaloTag-VEGFR2 were markedly overexpressed in our
HEK293T cells, we compared their relative expression levels
with those of native untransfected HEK293T and HUVECs using
quantitative immunohistochemistry with a selective VEGFR2
antibody (Figure S4). These data showed that the expression
levels of the tagged VEGFR2 variants were low and below the
native expression level of VEGFR2 in HUVECs (Figure S4).
Using VEGF165a-TMR, VEGF165b-TMR, and VEGF121a-TMR
as three distinct fluorescent probes, increasing concentrations
of unlabeled VEGF-Ax were used to inhibit the specific binding
of each concentration of fluorescent ligand to NanoLuc-VEGFR2
(0.25–3 nM) (Figures 3G–3I). These data were used to derive pKi
values for VEGF-Ax assuming mass action interactions (Table
S3). Binding affinities were also derived from similar experiments
with a comprehensive panel of unlabeled VEGF-A isoforms at
NanoLuc-VEGFR2 (Table S3). pKi values obtained for each
competing ligand were not significantly different between the
fluorescent VEGF probes used (one-way ANOVA).
Real-Time Binding of Fluorescent VEGF165a to NRP1
We were also able to apply the NanoBRET technology to the
type I single transmembrane co-receptor NRP1. NanoLuc was
fused to the extracellular N terminus of NRP1 and expressed in
HEK293T cells to isolate binding of the different fluorescent
VEGF-A isoforms to full-length NRP1. Specific binding of
VEGF165a-TMR to NanoLuc-NRP1 was clearly observed with
minimal non-specific binding following incubation for 60 min
(KD = 4.41 ± 1.34 nM, n = 5; Figure 4A). Kinetic binding measure-
ments also revealed that specific binding of VEGF165a-TMR to
NanoLuc-NRP1 was reached within 4 min and exhibited faster
kon (7.11 ± 2.33 3 10
7 min1 M1) and koff (0.26 ± 0.05 min
1)
rate constants than were achieved with this ligand at NanoLuc-
VEGFR2 (Figure 4B and Table 1). However, the equilibrium
dissociation constants were very similar for VEGF165a-TMR be-
tween NRP1 and VEGFR2 (Table 1). Displacing each concentra-
tion of VEGF165a-TMR (0.5–5 nM) by increasing concentrations
Figure 2. Co-localization of Fluorescent VEGF-A Isoform Binding and HaloTag-VEGFR2
Confocal images of HEK293T cells stably expressing HaloTag-VEGFR2 (green) stimulated with vehicle or 10 nM VEGF165a-TMR, VEGF165b-TMR, or VEGF121a-
TMR (red) for 1 hr at 37C. Cells were imaged live using a Zeiss LSM710 and are representative images of 3 independent experiments. Scale bar, 10 mm. See also
Figures S3 and S4.
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pKi of 9.54 ± 0.21 (Figure 4C, n = 5; Table S3). A linear relation-
ship was observed between the IC50 and VEGF165a-TMR con-
centration at NanoLuc-NRP1 (R2 = 0.95, p < 0.005; Figure 4D).
NRP1Expressed in LivingCells DoesNot Bind VEGF165b,
VEGF121a, VEGF-Ax, or VEGF111a
To investigate how the three distinct fluorescent VEGF isoforms
interacted with NRP1, we used VEGF165a-TMR alongside
VEGF165b-TMR and VEGF121a-TMR to image fluorescent
ligand binding to HaloTag-NRP1 expressed in HEK293T cells
and labeled with membrane-impermeant Alexa Fluor 488.
Upon both vehicle and fluorescent ligand application, HaloTag-
NRP1 remained at the cell surface (Figure 5A). While 10 nM
VEGF165a-TMR co-localized with HaloTag-NRP1 when imaged
after 60 min, no binding of VEGF165b-TMR and VEGF121a-TMR
to HaloTag-NRP1 was detected (Figure 5A). This latter observa-
tion was confirmed using NanoBRET, whereby no saturable
binding was detected between VEGF165b-TMR or VEGF121a-
TMR and NanoLuc-NRP1 (Figure 5B). Using 3 nM VEGF165a-
TMR as a fluorescent probe, only unlabeled VEGF165a,
VEGF145a, and VEGF189a displaced binding from NRP1 (Fig-
ure 5C). Full competition ligand binding experiments allowed
pKi values at NanoLuc-NRP1 to be determined for these latterVEGF-A isoforms (Table S3). Quantitative immunohistochem-
istry analysis confirmed that NanoLuc-NRP1 and HaloTag-
NRP1 were expressed at low levels in HEK293T cells (Figure S4).
NanoBRET was also used to investigate ligand binding at a
previously identified VEGF binding-dead mutant NRP1 Y297A,
lacking a key residue in the b1 domain responsible for VEGF
binding (Fantin et al., 2014). Having also confirmed membrane
expression of HaloTag-NRP1 Y297A using live cell imaging,
co-localization was absent for all three fluorescent VEGF iso-
forms (Figure 6A). Analogous BRET experiments showed that
VEGF165a-TMR did not interact with NanoLuc-NRP1 Y297A,
yielding BRET ratios that did not differ from vehicle (Figure 6B).
This confirmed NRP1 Y297A as a mutant deficient for VEGF
binding.
DISCUSSION
In the present study we have evaluated the ability of three fluo-
rescent analogs of VEGF (VEGF165a, VEGF165b, and VEGF121a)
to discriminate between VEGFR2 and NRP1 in living cells in
real time. To enable this, we prepared single-site (N-terminal
cysteine) labeled versions of VEGF165b and VEGF121a essentially
as described previously for VEGF165a (Kilpatrick et al., 2017).
These fluorescent ligands were used in combination withCell Chemical Biology 25, 1–11, October 18, 2018 5
Figure 3. Binding Characteristics of Fluorescent VEGF Isoforms to NanoLuc-VEGFR2 Expressed in HEK293 Cells
(A–C) HEK293T cells expressing N-terminal NanoLuc-VEGFR2 were incubated with increasing concentrations of (A) VEGF165a-TMR, (B) VEGF165b-TMR, or (C)
VEGF121a-TMR, in the presence and absence of 100 nM unlabeled VEGF, added simultaneously to define non-specific binding (60 min; 37
C). BRET ratios are
expressed as mean ± SEM from 5 independent experiments with duplicate wells. Where not shown, error bars are within the size of the symbol.
(D–F) Time course of (D) VEGF165a-TMR, (E) VEGF165b-TMR, or (F) VEGF121a-TMR ligand binding kinetics at NanoLuc-VEGFR2. Cells treated with furimazine
were left to equilibrate for 5 min before addition of 1–20 nM fluorescent VEGF ligand or vehicle, and measurements were taken every 30 s for 20 min (37C).
Baseline BRET ratios are corrected to vehicle at time zero. Data represent mean ± SEM from 5 independent experiments, and individual curves were fitted with a
simple exponential association model.
(G–I) Displacement of (G) VEGF165a-TMR, (H) VEGF165b-TMR, or (I) VEGF121a-TMR binding by unlabeled VEGF-Ax. Increasing concentrations of VEGF-Ax
were added in duplicate wells simultaneously with 5 separate fixed concentrations (0.25–3 nM) of VEGF165a-TMR, VEGF165b-TMR, or VEGF121a-TMR
(60 min, 37C). Raw BRET ratios from 5 independent experiments are shown as mean ± SEM with bars illustrating vehicle (white bars) or fluorescent VEGF-
TMR alone.
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VEGFR2 or NRP1 to evaluate the selectivity of VEGF isoforms
for these two membrane proteins. The close proximity require-
ments (<10 nm) of the interaction between fluorescent ligand
and receptor protein in order for bioluminescence transfer to
occur (for NanoBRET measurement) ensured a high specificity
of interaction, regardless of the extent of endogenous receptor
expression. This was important since, although HEK293T
did not express endogenous NRP1 (Figure S3), endogenous
VEGFR2 were detected in a subpopulation of untransfected
HEK293T cells. Furthermore, following expression of HaloTag-
labeled NRP1, the endogenous expression of VEGFR2 appeared6 Cell Chemical Biology 25, 1–11, October 18, 2018to increase (Figure S3). The expression level of VEGFR1 was,
however, minimal in both untransfected HEK293T cells and
those transfected with tagged variants of either VEGFR2
or NRP1.
VEGF165a-TMR, VEGF165b-TMR, and VEGF121a-TMR each
exhibited saturable binding to NanoLuc-VEGFR2 expressed in
HEK293T cells with nanomolar affinity. Furthermore, there
were minimal levels of non-specific binding detected with each
fluorescent ligand. Analysis of the real-time binding characteris-
tics of each fluorescent ligand indicated that all three fluorescent
VEGF variants had very similar kon and koff rate constants, and
indeed their off rates were very slow (koff = 0.05–0.06 min
1).
Table 1. Binding Characteristics of Fluorescent Ligands Binding to VEGFR2 or NRP1
Fluorescent Ligand Receptor Saturation KD (nM) Kinetic KD (nM) kon (min
1 M1) koff (min
1)
VEGF165a-TMR NanoLuc-VEGFR2 2.03 ± 0.51 6.64 ± 4.37 1.54 3 10
7 ± 0.38 3 107 0.06 ± 0.02
VEGF165b-TMR NanoLuc-VEGFR2 9.53 ± 1.36 11.3 ± 3.54 7.29 3 10
6 ± 1.84 3 106 0.06 ± 0.01
VEGF121a-TMR NanoLuc-VEGFR2 5.54 ± 1.34 5.75 ± 0.46 8.51 3 10
6 ± 0.81 3 106 0.05 ± 0.00
VEGF165a-TMR NanoLuc-NRP1 4.41 ± 1.34 4.95 ± 1.25 7.11 3 10
7 ± 2.33 3 107 0.26 ± 0.05
Equilibrium binding parameters for fluorescent VEGF isoforms derived from saturation and kinetic NanoBRET experiments, showing equilibrium disso-
ciation (KD), association rate (kon), and dissociation rate (koff) constants at NanoLuc-VEGFR2 and NanoLuc-NRP1. Data are expressed asmean ± SEM
determined from 5 independent experiments.
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isoforms, including the recently described VEGF-Ax (Eswarappa
et al., 2014), from competition experiments using all three of
the fluorescent probes. All seven ligands had comparable nano-
molar binding affinities for VEGFR2 ranging between 0.2 and
1.4 nM, in agreement with previous studies (Peach et al.,
2018), suggesting that potential differences in signaling re-
sponses of these isoforms is not due to binding alone (Whitaker
et al., 2001; Ce´be Suarez et al., 2006; Eswarappa et al., 2014; Kil-
patrick et al., 2017). There was no evidence of probe depen-
dence in the measurement of these equilibrium constants, sug-
gesting that the interactions could be described by simple
mass action interactions.
VEGF165a-TMR bound to NanoLuc-NRP1 in living cells with a
high affinity (4.41 nM) similar to that observed at NanoLuc-
VEGFR2 (2.03 nM). However, in marked contrast VEGF165b-
TMR and VEGF121a-TMR did not bind to NanoLuc-NRP1
(measured via NanoBRET) at concentrations up to 20 nM. This
observation was corroborated by live cell confocal imaging,
which showed that VEGF165b-TMR (10 nM) and VEGF121a-
TMR (10 nM) bound to HaloTag-VEGFR2 but not to HaloTag-
NRP1. The importance of residue Y297 (Fantin et al., 2014) of
NRP1 for the binding of VEGF165a was confirmed in HEK293Tdetermined in (C) and VEGF165a-TMR concentration. The y intercept provides
(0.09) represents the ratio Ki/KD thus yielding an estimated KD = 1.11 nM for Vcells expressing a Y297A mutant of NRP1. Competition binding
experiments at NanoLuc-NRP1 yielded a rank order of pKi values
of VEGF165a > VEGF189a > VEGF145a. In contrast, VEGF165b,
VEGF-Ax, VEGF121a, and VEGF111a were unable to displace
3 nM VEGF165a-TMR at concentrations up to 30 nM. These ob-
servations support previous reports that these isoforms may be
unable to bind NRP1 (Woolard et al., 2009). There have, how-
ever, been conflicting reports regarding VEGF121a binding to
NRP1 (reviewed in Sarabipour and Mac Gabhann, 2017). Thus,
although radioligand binding and solid-phase biotinylation as-
says have shown no interaction between VEGF121a and NRP1
(Ce´be Suarez et al., 2006; Kawamura et al., 2008; Xin et al.,
2016), low-affinity binding was detected using immobilized
monomeric NRP1 and surface plasmon resonance (SPR) or iso-
lated NRP1 b1/b2 domains (Pan et al., 2007; Parker et al., 2012;
Delcombel et al., 2013).
A key feature of the present study is the ability to study the
binding of VEGF-A isoforms to full-length VEGFR2 and NRP1
in living cells and in real time. This ensures that the interac-
tions studied are of physiological relevance (Djordjevic and
Driscoll, 2013). The lack of binding of VEGF165b, VEGF-Ax,
VEGF121a, and VEGF111a to NRP1 is seen at concentrations
up to 20 nM, which are far in excess of the predictedFigure 4. BindingCharacteristicsofVEGF165a
Binding to NanoLuc-NRP1
(A) Increasing concentrations of VEGF165a-TMR
were added to HEK293T cells stably expressing
N-terminal NanoLuc-NRP1 in the presence and
absence of 100 nM unlabeled VEGF165a to deter-
mine non-specific binding, and cells were incu-
bated for 60 min at 37C. Raw BRET ratios are
expressed as mean ± SEM from 5 independent
experiments.
(B) Time course of VEGF165a-TMR binding to
NanoLuc-NRP1. BRET ratios were baseline cor-
rected to vehicle, curves were fitted to a simple
exponential associationmodel, and data are shown
as mean ± SEM from 5 independent experiments.
(C) Inhibition of the binding of VEGF165a-TMR (0.5,
1, 2, 3, and 5 nM) to NanoLuc-NRP1 by increasing
concentrations of unlabeled VEGF165a added
simultaneously and incubated for 60 min at 37C.
RawBRET ratios from 5 independent displacement
experiments using duplicate wells are shown as
mean ± SEM with bars representing vehicle (white)
or VEGF165a-TMR only.
(D) Linear regression analysis (R2 = 0.95; p <
0.005) of the relationship between IC50 values
an estimate for the Ki of competing VEGF165a (0.10 nM), while the slope
EGF165a-TMR at NanoLuc-NRP1.
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Figure 5. Selective Binding of VEGF Iso-
forms at NRP1
(A) Confocal live cell imaging of fluorescently labeled
VEGF-TMR isoforms binding to N-terminal HaloTag-
NRP1 stably expressed in HEK293T cells. HaloTag-
NRP1 was tagged with the membrane-impermeant
HaloTag-AF488 dye (green) and then incubated
with 10 nM VEGF165a-TMR, VEGF165b-TMR, or
VEGF121a-TMR (red) for 60 min at 37
C. Cells were
imaged using an LSM710 confocal microscope and
images are representative of those obtained in 3 in-
dependent experiments. Scale bar, 10 mm.
(B) NanoLuc-NRP1 HEK293T cells were incubated
with increasing concentrations of VEGF165a-TMR,
VEGF165b-TMR, or VEGF121a-TMR and incubated
for 60 min at 37C. Raw BRET ratios are ex-
pressed as mean ± SEM from 3–4 independent
experiments.
(C) Inhibition of VEGF165a-TMR (3 nM) by competing
unlabeled VEGF isoforms (30 nM), added simulta-
neously and incubated for 60 min at 37C. Data are
normalized to 3 nM VEGF165a-TMR (100%, black
bar) and represent mean ± SEM pooled from 5 in-
dependent experiments. Statistical analyses
were performed using Welch’s t test: ***p% 0.001;
****p% 0.0001.
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Gabhann, 2017). These data suggest that VEGF165b-TMR
and VEGF121a-TMR can be used as selective fluorescent
probes for VEGFR2, even in cells that also express endoge-
nous NRP1.
Real-time analysis of the binding of VEGF165a-TMR to
NanoLuc-NRP1 expressed in HEK293T cells enabled the ki-
netics of ligand binding to be monitored to these membrane
proteins for the first time. Despite comparable equilibrium disso-
ciation constants determined by saturation and kinetic binding
experiments, VEGF165a-TMR had faster binding kinetics at
NRP1 compared with VEGFR2. Maximum specific binding to
NanoLuc-NRP1 could be achieved within 5 min largely as a
consequence of its very fast koff (0.26 min
1). These data sug-
gest that in cells expressing both VEGFR2 and NRP1, VEGF165a
will bind more quickly to NRP1 than to VEGFR2, particularly at
low agonist concentrations. This may have important implica-
tions for the dynamics of VEGF signaling, and emphasize the
need to understand the kinetic aspects of ligand binding to
VEGFR2 and its co-receptors as well as the temporal aspects
of intracellular signaling. Thus, since
t1=2 =
0:693
kon x ½A+ koff8 Cell Chemical Biology 25, 1–11, October 18, 2018for 1 nM VEGF165a-TMR using the param-
eters provided in Table 1, the t1/2 for
association to VEGFR2 will be 9.2 min
while that for NRP1 will be 2.1 min. For
10 nM VEGF165a-TMR the t1/2 values are
3.2 min and 0.7 min for VEGFR2 and
NRP1, respectively.
Imaging ligand/receptor interactions
using a membrane-impermeant HaloTaglabel also highlighted distinct differences in the subcellular distri-
butions of VEGFR2 and NRP1, and the consequences of incuba-
tion with VEGF165a. HaloTag-VEGFR2 was constitutively inter-
nalized in the absence of ligand stimulation. This agrees with
previous antibody-based imaging in HUVECs and human micro-
vascular endothelial cells (Gampel et al., 2006; Basagiannis and
Christoforidis, 2016; Basagiannis et al., 2016), and our own
studies using VEGFR2 stably expressed in HEK293T cells (Kilpa-
trick et al., 2017). Furthermore, VEGF165a-TMR, VEGF165b,
and VEGF121a were able to stimulate VEGFR2 internalization.
In contrast, HaloTag-NRP1, labeled with a cell-impermeant
HaloTag dye, was largely expressed on the cell membrane of
HEK293T cells and remained at the cell surface despite 60 min
of stimulation with a high concentration of VEGF165a-TMR.
Furthermore, VEGF165a-TMR only labeled membrane-ex-
pressed NRP1. Other groups have shown an intracellular
NRP1 distribution using permeabilized fluorescent antibody la-
beling (Narazaki and Tosato, 2006; Ballmer-Hofer et al., 2011).
However, it is clear from the present work that cell membrane
NRP1 is the primary target for VEGF165a and that this VEGF-A
isoform does not stimulate internalization of NRP1.
It has been previously noted that fluorescent ligands can have
pharmacological properties very different from their unlabeled
counterparts and that they should be evaluated as new chemical
Figure 6. The NRP1 Mutant Y297A Is Unable
to Bind Any VEGF Isoforms
(A) Live confocal imaging of HEK293T cells stably
expressing mutant HaloTag-NRP1 Y297A (green)
labeled with membrane-impermeant HaloTag-
AF488 dye (green). Cells were stimulated with
10 nM VEGF165a-TMR, VEGF165b-TMR, or
VEGF121a-TMR for 60 min at 37
C. Cells were
imaged using an LSM710 confocal microscope,
and images are representative images of 3 inde-
pendent experiments. Scale bar, 10 mm.
(B) NanoBRET measurements of the effect of un-
labeled VEGF isoforms (30 nM) on the binding of
3 nM VEGF165a-TMR to wild-type NanoLuc-NRP1
or NanoLuc-NRP1 Y297A stably expressing
HEK293T for 60 min (37C). Raw BRET ratios are
expressed as mean ± SEM pooled from 4 inde-
pendent experiments.
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that VEGF165a-TMR behaves very similarly to VEGF165a in its
ability to (1) stimulate NFAT reporter gene responses in
HEK293T cells expressing wild-type VEGFR2 and (2) enable pro-
liferation of HUVECs (Kilpatrick et al., 2017). However, both
VEGF165b-TMR and VEGF121a-TMR behave differently in func-
tional assays to VEGF165b and VEGF121a prepared in an identical
way to the fluorescent probes. Thus, in NFAT assays the EC50
values obtained with both VEGF165b-TMR (pEC50 = 8.28) and
VEGF121a-TMR (pEC50 = 8.57) were an order of magnitude
higher (less potent) than the non-fluorescent versions. However,
these EC50 values were very similar to the pKD values obtained
from saturation binding studies (7.9–8.1 for VEGF165b-TMR
and 8.2–8.4 for VEGF121a-TMR) and from competition binding
studies (9.29–9.30 for VEGF165b and 9.16–9.59 for VEGF121a).
This suggests that the differences were predominantly affinity
based and that there was little signal amplification in the NFAT
assay. Comparison of the agonist effects of fluorescent
VEGF165b and VEGF121a on pY1212 phosphorylation, however,
indicated that they produced the same maximal response as
their unlabeled counterparts. In the HUVEC proliferation assay
both VEGF165b-TMR and VEGF121a-TMR appeared to be of
lower efficacy than the non-fluorescent ligands but still showedCell Chepartial agonism in stimulating HUVEC
proliferation. Taken together, these
data suggest that VEGF165b-TMR and
VEGF121a-TMR, unlike VEGF165a-TMR,
are lower-affinity and lower-efficacy ago-
nists at VEGFR2 than their unlabeled ana-
logs. Furthermore, the extent of agonist ac-
tivity appears to depend on the signaling
pathway being monitored. This may indi-
cate anability for thesefluorescent analogs
to exhibit some signaling bias in a similar
way to that seen with G-protein-coupled
receptors (Smith et al., 2018).
In summary, fluorescent VEGF isoforms
were used to probe the pharmacology of
VEGFR2 and its co-receptor NRP1 in
living cells in real time at 37C. Despite
approved therapeutics targeting VEGF/VEGFR2 (Ferrara and
Adamis, 2016), this is the first comprehensive ligand binding
study of the interactions of a range of VEGF isoforms with both
full-length VEGFR2 and NRP in living cells. The real-time sensi-
tivity of NanoBRET revealed clear differences in the kinetic bind-
ing profiles of VEGF165a-TMR for NRP1 and VEGFR2, despite
this ligand having a very similar equilibrium dissociation binding
constant for each membrane protein. All VEGF isoforms studied
had a similar high affinity for VEGFR2 but not all isoforms inter-
acted with NRP1. In particular, VEGF165b-TMR and VEGF121a-
TMR were not able to bind to NRP1 at physiologically relevant
concentrations. These two partial agonist ligands should there-
fore be important and selective probes for the study of VEGFR2
in cells also expressing NRP1. Furthermore, our study also em-
phasizes the importance of the kinetic aspects of ligand binding
to VEGFR2 and its co-receptors in the overall dynamics of VEGF
signaling.
SIGNIFICANCE
VEGF-A is an essential mediator of angiogenesis that sig-
nals via VEGFR2. We have synthesized fluorescent VEGF-A
isoforms and demonstrate that they can discriminatemical Biology 25, 1–11, October 18, 2018 9
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ligand binding studies. We have used a precision chemical
biology approach in live cells to accurately define the bind-
ing characteristics of specific VEGF-A isoforms and to
determine which isoforms can bind to NRP1 at concentra-
tions required to occupy VEGFR2. Only VEGF165a, VEGF145a,
and VEGF189a are able to also bind toNRP1. Furthermore, we
have shown that while VEGF165a-TMR has a similar equilib-
rium binding affinity for VEGFR2 and NRP1, it binds more
rapidly to NRP1 than to VEGFR2. We have also shown that
VEGF165a-TMR has a shorter residence time (1/koff) at
NRP1 (3.8 min) than VEGFR2 (16.6 min). These fluorescent li-
gands should therefore serve as valuable probes to interro-
gate the roles of VEGFR2 and NRP1 in angiogenesis and
signaling.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
d METHOD DETAILSB Cell Culture
B DNA Constructs
B Fluorescent Ligand Synthesis
B NFAT Luciferase Reporter Gene Assay
B VEGFR2 Phosphorylation Assay
B HUVEC Proliferation Assay
B Measuring Ligand Binding Using NanoBRET
B Live Cell Confocal Imaging
B Fluorescence Correlation Spectroscopy (FCS)
B Immunofluorescence Labelling
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Data Analysis
B High Content Imaging
B FCS Autocorrelation Analysis
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and three tables and can be
found with this article online at https://doi.org/10.1016/j.chembiol.2018.
06.012.
ACKNOWLEDGMENTS
This work was supported by the Biotechnology and Biological Sciences
Research Council (grant number BB/L019418/1) and Promega Corporation.
C.P. was funded by an A.J. Clark studentship from the British Pharmacological
Society (BPS). We thank Dave Good and Sergy Levin for the synthesis of
6-TMR-PEG-CBT and Mike Rosenblatt for the LC-MS/MS analysis. We also
thank the School of Life Sciences Imaging (SLIM) team for maintenance and
support for high content and confocal imaging facilities.
AUTHOR CONTRIBUTIONS
Conceptualization, S.J.H., J.W., and L.E.K.; Methodology, S.J.H., L.E.K.,
R.F.-O., and K.Z.; Formal analysis, C.J.P., L.E.K., S.J.H. and R.F.-O.; Investi-
gation, C.J.P., L.E.K., R.F.-O., M.B.R., S.J.H., and J.W.; Writing – Original10 Cell Chemical Biology 25, 1–11, October 18, 2018Draft, C.J.P., L.E.K., and S.J.H.; Writing – Review and Editing, C.J.P., L.E.K.,
K.V.W., M.B.R., R.F.-O, J.W., and S.J.H; Supervision, S.J.H., J.W., and L.E.K.
DECLARATION OF INTERESTS
R.F.-O., M.B.R., K.Z., and K.V.W. are employees of Promega Corporation,
which has proprietary rights over the NanoBRET assay, HaloTag technology,
and CBT labeling technology.
Received: February 2, 2018
Revised: May 23, 2018
Accepted: June 29, 2018
Published: July 26, 2018
REFERENCES
Ballmer-Hofer, K., Andersson, A.E., Ratcliffe, L.E., and Berger, P. (2011).
Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby
specifying signal output. Blood 118, 816–826.
Basagiannis, D., and Christoforidis, S. (2016). Constitutive endocytosis of
VEGFR2 protects the receptor against shedding. J. Biol. Chem. 291,
16892–16903.
Basagiannis, D., Zografou, S., Murphy, C., Fotsis, T., Morbidelli, L., Ziche, M.,
Bleck, C., Mercer, J., and Christoforidis, S. (2016). VEGF induces signalling
and angiogenesis by directing VEGFR2 internalisation via macropinocytosis.
J. Cell Sci. 129, 4091–4104.
Cai, H., and Reed, R.R. (1999). Cloning and characterization of neuropilin-1-in-
teracting protein: a PSD- 95/Dlg/ZO-1 domain-containing protein that inter-
acts with the cytoplasmic domain of neuropilin-1. J. Neurosci. 19, 6519–6527.
Carter, J., Wheal, A., Hill, S., and Woolard, J. (2015). Effects of receptor tyro-
sine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcrip-
tion in HEK-293 cells expressing human VEGFR2. Br. J. Pharmacol. 172,
3141–3150.
Ce´be Suarez, S., Pieren, M., Cariolato, L., Arn, S., Hoffman, U., Bogucki, A.,
Manlius, C., Wood, J., and Ballmer-Hofer, K. (2006). A VEGF-A splice variant
defective for heparan sulfate and neuropilin-1 binding shows attenuated
signaling through VEGFR-2. Cell. Mol. Life Sci. 63, 2067–2077.
Chittenden, T.W., Claes, F., Lanahan, A.A., Autiero, M., Palac, R.T.,
Tkachenko, E.V., Elfenbein, A., Ruiz de Almodovar, C., Dedkov, E.,
Tomanek, R., et al. (2006). Selective regulation of arterial branching morpho-
genesis by synectin. Dev. Cell 10, 783–795.
Chung, A.S., and Ferrara, N. (2011). Developmental and pathological angio-
genesis. Annu. Rev. Cell Dev. Biol. 27, 563–584.
Clegg, L.E., and Mac Gabhann, F. (2017). A computational analysis of in vivo
VEGFR activation by multiple co-expressed ligands. PLoS Comput. Biol. 13,
e1005445.
Cunningham, S.A., Arrate, M.P., Brock, T.A., and Waxham, M.N. (1997).
Interactions of FLT-1 and KDR with phospholipase Cg: identification of
the phosphotyrosine binding sites. Biochem. Biophys. Res. Commun. 240,
635–639.
Delcombel, R., Janssen, L., Vassy, R., Gammons,M., Haddad, O., Richard, B.,
Letourneur, D., Bates, D., Hendricks, C., Waltenberger, J., et al. (2013). New
prospects in the roles of the C-terminal domains of VEGF-A and their cooper-
ation for ligand binding, cellular signaling and vessels formation. Angiogenesis
16, 353–371.
Djordjevic, S., and Driscoll, P.C. (2013). Targeting VEGF signalling via the neu-
ropilin co-receptor. Drug Discov. Today 18, 447–455.
Eswarappa, S.M., Potdar, A.A., Koch, W.J., Fan, Y., Vasu, K., Lindner, D.,
Willard, B., Graham, L.M., Dicorleto, P.E., and Fox, P.L. (2014). Programmed
translational readthrough generates antiangiogenic VEGF-Ax. Cell 157,
1605–1618.
Fantin, A., Schwarz, Q., Davidson, K., Normando, E.M., Denti, L., and
Ruhrberg, C. (2011). The cytoplasmic domain of neuropilin 1 is dispensable
for angiogenesis, but promotes the spatial separation of retinal arteries and
veins. Development 138, 4185–4191.
Please cite this article in press as: Peach et al., Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and
NRP1 in Living Cells, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.06.012Fantin, A., Herzog, B., Mahmoud, M., Yamaji, M., Plein, A., Denti, L., Ruhrberg,
C., and Zachary, I. (2014). Neuropilin 1 (NRP1) hypomorphism combined with
defective VEGF-A binding reveals novel roles for NRP1 in developmental and
pathological angiogenesis. Development 141, 556–562.
Ferrara, N., and Adamis, A.P. (2016). Ten years of anti-vascular endothelial
growth factor therapy. Nat. Rev. Drug Discov. 15, 385–403.
Gampel, A., Moss, L., Jones, M.C., Brunton, V., Norman, J.C., and Mellor, H.
(2006). VEGF regulates the mobilization of VEGFR2/KDR from an intracellular
endothelial storage compartment. Blood 108, 2624–2631.
Goel, H.L., and Mercurio, A.M. (2013). VEGF targets the tumour cell. Nat. Rev.
Cancer 13, 871–882.
Gu, C., Rodriguez, E.R., Reimert, D.V., Shu, T., Fritzsch, B., Richards, L.J.,
Kolodkin, A.L., and Ginty, D.D. (2003). Neuropilin-1 conveys semaphorin and
VEGF signaling during neural and cardiovascular development. Dev. Cell
5, 45–57.
Guo, H.F., and Vander Kooi, C.W. (2015). Neuropilin functions as an essential
cell surface receptor. J. Biol. Chem. 290, 29120–29126.
Harper, S.J., and Bates, D. (2008). VEGF-A splicing: the key to anti-angiogenic
therapeutics? Nat. Rev. Cancer 8, 880–887.
Jubb, A.M., Strickland, L.A., Liu, S.D., Mak, J., Schmidt, M., and Koeppen, H.
(2012). Neuropilin-1 expression in cancer and development. J. Pathol.
226, 50–60.
Kawamura, H., Li, X., Harper, S., Bates, D., and Claesson-Welsh, L. (2008).
Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for
VEGF receptor-2 due to lack of coreceptor binding and deficient regulation
of kinase activity. Cancer Res. 68, 4683–4692.
Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuda, Y., Sanbo, M., Yagi, T., and
Fujisawa, H. (1999). A requirement for neuropilin-1 in embryonic vessel forma-
tion. Development 126, 4895–4902.
Kilpatrick, L.E., Friedman-Ohana, R., Alcobia, D.C., Riching, K., Peach, C.J.,
Wheal, A.J., Briddon, S.J., Robers, M.B., Zimmerman, K., Machleidt, T.,
et al. (2017). Real-time analysis of the binding of fluorescent VEGF165a to
VEGFR2 in living cells: effect of receptor tyrosine kinase inhibitors and fate
of internalized agonist-receptor complexes. Biochem. Pharmacol. 136, 62–75.
Kitsukawa, T., Shimizu, M., Sanbo, M., Hirata, T., Taniguchi, M., Bekku, Y.,
Yagi, T., and Fujisawa, H. (1997). Neuropilin–semaphorin III/D-mediated che-
morepulsive signals play a crucial role in peripheral nerve projection in mice.
Neuron 19, 995–1005.
Koch, S., Tugues, S., Li, X., Gualandi, L., andClaesson-Welsh, L. (2011). Signal
transduction by vascular endothelial growth factor receptors. Biochem. J. 437,
169–183.
Lanahan, A., Zhang, X., Fantin, A., Zhuang, Z., Rivera-Molina, F., Speichinger,
K., Prahst, C., Zhang, J., Wang, Y., Davis, G., et al. (2013). The neuropilin 1
cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. Dev.
Cell 25, 156–168.
Lee, S.W., Lee, J.E., Yoo, C.Y., Ko, M.S., Park, C.S., and Yang, S.H. (2014).
NRP-1 expression is strongly associated with the progression of pituitary ad-
enomas. Oncol. Rep. 32, 1537–1542.
Machleidt, T., Woodroofe, C.C., Schwinn, M.K., Me´ndez, J., Robers, M.,
Zimmerman, K., Otto, P., Daniels, D.L., Kirkland, T.A., and Wood, K.B.
(2015). NanoBRET—a novel BRET platform for the analysis of protein-protein
interactions. ACS Chem. Biol. 10, 1797–1804.
Narazaki, M., and Tosato, G. (2006). Ligand-induced internalization selects
use of common receptor neuropilin-1 by VEGF165 and semaphorin3A.
Blood 107, 3892–3901.Pan, Q., Chathery, Y., Wu, Y., Rathore, N., Tong, R., Peale, F., Bagri, A.,
Tessier-Lavigne, M., Koch, A.W., and Watts, R.J. (2007). Neuropilin-1 binds
to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol.
Chem. 282, 24049–24056.
Parker, M.W., Xu, P., Guo, H.F., and Vander Kooi, C.W. (2012). Mechanism of
selective VEGF-a binding by neuropilin-1 reveals a basis for specific ligand in-
hibition. PLoS One 7, e49177.
Peach, C.J., Mignone, V.W., Augusta Arruda, M., Alcobia, D.C., Hill, S.J.,
Kilpatrick, L.E., and Woolard, J. (2018). Molecular pharmacology of VEGF-A
isoforms: binding and signalling at VEGFR2. Int. J. Mol. Sci. 19, 1264.
Prahst, C., He´roult, M., Lanahan, A.A., Uziel, N., Kessler, O., Shraga-Heled, N.,
Simons, M., Neufeld, G., and Augustin, H.G. (2008). Neuropilin-1-VEGFR-2
complexing requires the PDZ-binding domain of neuropilin-1. J. Biol. Chem.
283, 25110–25114.
Ruch, C., Skiniotis, G., Steinmetz, M.O.,Walz, T., and Ballmer-Hofer, K. (2007).
Structure of a VEGF–VEGF receptor complex determined by electron micro-
scopy. Nat. Struct. Mol. Biol. 14, 249–250.
Sarabipour, S., and Mac Gabhann, F. (2017). VEGF-A121a binding to neuropi-
lins—a concept revisited. Cell Adh. Migr. https://doi.org/10.1080/19336918.
2017.1372878.
Shibuya, M. (2011). Vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic
therapies. Genes Cancer 2, 1097–1105.
Simons, M., Gordon, E., and Claesson-Welsh, L. (2016). Mechanisms and
regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol.
17, 611–625.
Smith, J.S., Lefkowitz, R.J., and Rajagopal, S. (2018). Biased signalling: from
simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. 17,
243–269.
Stoddart, L.A., Johnstone, E.K.M., Wheal, A.J., Goulding, J., Robers, M.B.,
Machleidt, T., Wood, K.V., Hill, S.J., and Pfleger, K.D.G. (2015). Application
of BRET to monitor ligand binding to GPCRs. Nat. Methods 12, 661–663.
Stoddart, L.A., White, C.W., Nguyen, K., Hill, S.J., and Pfleger, K.D. (2016).
Fluorescence- and bioluminescence-based approaches to studyGPCR ligand
binding. Br. J. Pharmacol. 173, 3028–3037.
Stoddart, L.A., Kilpatrick, L.E., and Hill, S.J. (2018). NanoBRET approaches to
study ligand binding to GPCRs and RTKs. Trends Pharmacol. Sci. 39,
136–147.
Wang, L., Mukhopadhyay, D., and Xu, X. (2006). C terminus of RGS-GAIP-in-
teracting protein conveys neuropilin-1-mediated signaling during angiogen-
esis. FASEB J. 20, 1513–1515.
Whitaker, G.B., Limberg, B.J., and Rosenbaum, J.S. (2001). Vascular endothe-
lial growth factor receptor-2 and neuropilin-1 form a receptor complex that is
responsible for the differential signaling potency of VEGF165 and VEGF121.
J. Biol. Chem. 276, 25520–25531.
Woolard, J., Wang, W., Bevan, H.S., Qiu, Y., Morbidelli, L., Pritchard-Jones,
R.O., Cui, T., Sugiono, M., Waine, E., Perrin, R., et al. (2004). VEGF165b, an
inhibitory vascular endothelial growth factor splice variant: mechanism of ac-
tion, in vivo effect on angiogenesis and endogenous protein expression.
Cancer Res. 64, 7822–7835.
Woolard, J., Bevan, H.S., Harper, S.J., and Bates, D. (2009). Molecular diver-
sity of VEGF-A as a regulator of its biological activity. Microcirculation 16,
572–592.
Xin, H., Zhong, C., Nudleman, E., and Ferrara, N. (2016). Evidence for pro-
angiogenic functions of VEGF-Ax. Cell 167, 275–284.Cell Chemical Biology 25, 1–11, October 18, 2018 11
Please cite this article in press as: Peach et al., Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and
NRP1 in Living Cells, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.06.012STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-VEGFR1 Sigma Aldrich Cat# V4762 RRID:AB_477622
Mouse monoclonal anti-VEGFR2 Sigma Aldrich Cat# V9134 RRID:AB_477630
Goat polyclonal anti-Neuropilin-1 Santa Cruz Cat# SC7239 RRID:AB_2150835
Rabbit monoclonal anti-VEGFR2 phosphoY1212 Cell Signalling Technology Cat# 2477S RRID:AB_331374
Chemicals, Peptides, and Recombinant Proteins
VEGF165a R&D Systems (Abingdon, UK) Cat# 293-VE
VEGF165b R&D Systems (Abingdon, UK) Cat# 3045-VE
VEGF121a R&D Systems (Abingdon, UK) Cat# 4644-VS
VEGF145a R&D Systems (Abingdon, UK) Cat# 7626-VE
VEGF189a R&D Systems (Abingdon, UK) Cat# 8147-VE
VEGF111a R&D Systems (Abingdon, UK) Cat# 5336-VE
VEGF-Ax R&D Systems (Abingdon, UK) Cat# 9018-VE
HaloTag AlexaFluor 488 membrane impermeant
substrate
Promega Corporation (Wisconsin, USA) Cat# G1002
bisBenzimide H 33342 trihydrochloride Sigma Aldrich Cat# B2261
Formaldehyde solution 4% Sigma Aldrich Cat# F8775
Cediranib Sequoia Research Products Cat# SRP01883c
Chromasolv Sigma Aldrich Cat# 34877
Rhodamine 6G Sigma Aldrich Cat# R4127
Triton-X-100 (laboratory grade) Sigma Aldrich Cat# X100
DTT 1,4-Dithiothreitol Sigma Aldrich Cat# DTT-RO
PNGase F Promega Corporation (Wisconsin, USA) Cat# V4831
Protease-free bovine serum albumin Milpore Cat# 126609
Protease-free bovine serum albumin Sigma Aldrich Cat# 03117332001
Secondary chick anti-mouse Invitrogen Cat# A21463
Secondary donkey anti-goat Invitrogen Cat# A11056
Secondary chick anti-rabbit AlexaFluor-488 ThermoFisher Scientific, USA Cat# A-21441
Chicken serum Sigma Aldrich Cat# C5405
Donkey serum Sigma Aldrich Cat# D9663
ProLong Gold antifade reagent ThermoFisher Scientific, USA Cat# P10144
Dulbecco’s Modified Eagle’s Medium Sigma Aldrich Cat# D6429
Fetal Bovine Serum Sigma Aldrich Cat# F2442
Medium 200 (Gibco) ThermoFisher Scientific, USA Cat# M-200-500
Large Vessel Endothelial Supplement
(LVES 50x) (Gibco)
ThermoFisher Scientific, USA Cat# A1460801
Poly-D-Lysine hydrobromide Sigma Aldrich Cat# P6407
Dulbecco’s Phosphate Buffered Saline (DPBS) Sigma Aldrich Cat# D8537
Trypsin-EDTA solution x10 Sigma Aldrich Cat# T4174
Critical Commercial Assays
HaloTag Mammalian Protein Detection and
Purification System
Promega Corporation (Wisconsin, USA) Cat# G6795
ONE-GloTM Luciferase Promega Corporation (Wisconsin, USA) Cat# E6120
Nano-Glo luciferase assay system (Furimazine) Promega Corporation (Wisconsin, USA) Cat# N1130
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Experimental Models: Cell Lines
Human: GloResponse NFAT-RE-luc2P HEK293
cell line (female)
Promega Corporation (Wisconsin, USA) Cat# E8510
Human: HUVEC cells (newborn male, single donor) ThermoFisher Scientific Cat# C0035C. Lot number: 1606186.
Human: HEK293T cells (female) ATCC (Virginia, USA) Cat# CRL-3216
Recombinant DNA
NanoLuc-VEGFR2 Promega Corporation (Wisconsin, USA) Custom synthesis
NanoLuc-NRP1 Promega Corporation (Wisconsin, USA) Custom synthesis
NanoLuc-NRP1 Y297A Promega Corporation (Wisconsin, USA) Custom synthesis
HaloTag-VEGFR2 Promega Corporation (Wisconsin, USA) Custom synthesis
HaloTag-NRP1 Promega Corporation (Wisconsin, USA) Custom synthesis
HaloTag-NRP1 Y297A Promega Corporation (Wisconsin, USA) Custom synthesis
VEGF165a Gene Dynamics LLC (Oregon, USA) Custom synthesis
VEGF165b Gene Dynamics LLC (Oregon, USA) Custom synthesis
VEGF121a Gene Dynamics LLC (Oregon, USA) Custom synthesis
pFN21 HaloTag CMV Flexi Vector (modified to
contain a IL-6 secretion sequence and a
EPTTEDLYFQCDN linker sequence)
Promega Corporation (Wisconsin, USA) Cat# G2821
Software and Algorithms
GraphPad Prism 7.02 GraphPad Software, La Jolla
California USA
www.graphpad.com
Zen 2010 Zeiss, Germany www.zeiss.com
MetaXpress Molecular Devices, USA www.moleculardevices.com
Other
Black 96-well plates Greiner Bio-One Cat# 655090
White 96-well plates Greiner Bio-One Cat# 655098
8-well plates Nunc Lab-Tek, Thermo Fisher Scientific Cat# 155411
Coverslips (18x18mm; 1.5H) Zeiss, Germany Cat# 474030-9000-000
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephen
J. Hill (stephen.hill@nottingham.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
HUVECs (obtained from a single newborn male donor) and HEK293T (female) cells were transfected and cultured as described in
Method Details.
METHOD DETAILS
Cell Culture
HEK293T cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich, USA) supplemented with 10%Fetal Calf
Serum (FCS; Sigma-Aldrich, USA) at 37C/5% CO2. Cells were passaged at 70-80% confluency using Phosphate Buffered Saline
(PBS; Lonza, Switzerland) and trypsin (0.25% w/v in versene; Lonza). Stable and transient transfections were performed using
FuGENE HD (Promega Corporation, USA) at a reagent to cDNA ratio of 3:1. Human umbilical vein endothelial cells (HUVECs;
C0035C, Thermo Fisher Scientific, USA) were grown at 37C/5% CO2 in Medium 200 containing 10% Large Vessel Endothelial
Supplement (LVES, 50X; Thermo Fisher Scientific, USA) and passaged at 80-90% confluency between passages 4 to 9.
DNA Constructs
For N terminal NanoLuc tagged wildtype VEGFR2 (NM_002253; Genscript, New Jersey, USA) or NRP1 constructs (NM_003873.5;
Kazusa DNA Research Institute (Japan) the appropriate cDNA was cloned into a pF-sNnK CMV/neo vector (Promega Corporation;Cell Chemical Biology 25, 1–11.e1–e5, October 18, 2018 e2
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frames which encoded a secreted NanoLuc fused via a Gly-Ser-Ser-Gly (AIA) linker to the N terminus of wildtype VEGFR2 or NRP1
(termed NanoLuc VEGFR2 or NRP1 respectively). For N terminal HaloTag constructs, wildtype VEGFR2 or NRP1 cDNA was cloned
into a pFN21A CMV/neo flexi vector (Promega Corporation; G2821) encoding a fusion of the secretory signal peptide sequence of
IL-6 onto the N terminus of HaloTag. The resultant ORFs encoded a secreted HaloTag fused via a EPTTEDLYFQSDN(AIA) linker to the
N terminus of NRP1 (HaloTag VEGFR2 or NRP1).
Fluorescent Ligand Synthesis
VEGF-A isoforms VEGF165a, VEGF165b and VEGF121a labelled at a single N-terminal cysteine residue with 6- tetramethylrhodamine
(TMR)-PEG-CBT were synthesised and purified using the HaloTag mammalian protein detection and purification system (G6795;
Promega Corporation, USA) alongside unlabelled analogues prepared identically (as described in Kilpatrick et al., 2017). To generate
labelled isoforms, the HaloTEV proteolytic release was done in the presence of 100mM TCEP and 4x molar excess of 6-TMR-PEG-
CBT. This step generated VEGF isoforms with an N-terminal cysteine that served as single point of conjugation with 6-TMR-PEG-
CBT. The purified labelled isoforms were dialyzed for 24 hours (50mM HEPES, 150mM NaCl) to remove the unconjugated
6-TMR-PEG-CBT and TCEP and stored in 2.5mg/ml protease-free bovine serum albumin (BSA; Millipore, USA) at -80C. Labelling
specificity and efficiency was determined using liquid chromatography-tandem mass spectrometry (LC-MS). SDS-PAGE assays in
the presence and absence of 100mM dithiothreitol (DTT; Sigma-Aldrich, UK) or PNGase (Promega Corporation, USA) were used to
measure dimerisation and glycosylation status respectively (detailed in Kilpatrick et al., 2017). Ligands were stored in 2.5mg/ml pro-
tease-free bovine serum albumin (BSA; Millipore, USA). Labelling specificity and efficiency was determined using liquid chromatog-
raphy-tandem mass spectrometry (LC-MS). SDS-PAGE assays in the presence and absence of dithiothreitol (DTT; Sigma-Aldrich,
UK) or PNGase (Promega Corporation, USA) were used to measure dimerisation and glycosylation status respectively (detailed in
Kilpatrick et al., 2017).
NFAT Luciferase Reporter Gene Assay
HEK293T cells stably expressing both wild type VEGFR2 and the Firefly luciferase reporter gene ReLuc2P (Promega Corporation,
USA) inserted downstream of the NFAT promoter were used to monitor NFAT-induced gene transcription following VEGFR2 activa-
tion (Carter et al., 2015). On the day of experimentation, cells grown to 95-100% confluency were plated in white-sided 96 well plates
(Greiner Bio-One, 655089) at 44,000 cells/well, and incubated for 1 hour in 100ml/well serum free DMEM/0.1% BSA (37C/5% CO2).
Cells were stimulated in duplicate wells with increasing concentrations of VEGF121a-TMR, VEGF165b-TMR or equivalent unlabelled
VEGF isoforms (synthesised in an identical manner to the fluorescent variant), then incubated for 5 hours at 37C/5% CO2. ONE-Glo
Luciferase reagent (Promega Corporation, USA) was then added at 100ml/well and luminescence was measured using a TopCount
platereader (Perkin Elmer, UK) following a 5 minute delay allowing reagent to react with luciferase and background luminescence to
subside.
VEGFR2 Phosphorylation Assay
HEK293T cells stably expressing NanoLuc-VEGFR2 were seeded at 15,000 cells/well in black flat-bottomed 96-well plates (Greiner
Bio-One, 655090) pre-coated with poly-D-lysine (0.01mg/ml in PBS). Following 24 hours, cells were serum starved and grown for
another 24 hours (37C/5%CO2), with additional 1 hour serum starving step prior to experimentation. For negative control wells, cells
were pre-incubated for 30 minutes with 1mM cediranib (Sequoia Research Products, UK). Cells were then stimulated for 20 minutes
with 30nM VEGF165b-TMR or VEGF121a-TMR, commercially available VEGF165a, VEGF165b or VEGF121a (R&D Systems) and
VEGF165b or VEGF121a prepared identically to the fluorescent analogues, in the presence of absence of negative control 1mM cedir-
anib. Cells were washed with 100ml/well PBS, fixed with 3% paraformaldehyde (PFA)/PBS for 20min at room temperature (RT),
washed (3x5min PBS), permeabilised with 0.025% Triton-X-100 in PBS, washed (3x5min PBS) and incubated with 3% BSA/1%
glycine/PBS to reduce non-specific binding (30mins, RT). After washing (3x5min PBS), cells were blocked with 10% chick serum
in PBS (30min, RT) and incubated at 4Covernight with rabbit monoclonal anti-VEGFR2 phosphoY1212 (Cell Signalling, 2477) diluted
1:200 in 10%chick serum/PBS. Cells werewashed (3x5min PBS) and incubated in the darkwith secondary antibody chick anti-rabbit
AlexaFluor488 (Thermo Fisher, A21441). Nuclei were stained with 2mg/ml H33342 (15min, RT), washed and stored at 4C in PBS.
Cells were imaged using an ImageXpress Micro widefield platereader (Molecular Devices, USA) with a 20x objective at 4 sites per
well using FITC and DAPI filters (exposure 1500ms and 25ms respectively).
HUVEC Proliferation Assay
HUVECs (passage 4-9) were seeded at 5,000 cells/well in black flat-bottomed 96-well plates (Greiner Bio-One, 655090) in 10%LVES/
Medium 200. Following 24 hours of cell growth at 37C/5% CO2, plating medium was replaced with Medium 200 containing 0.1%
serum for 24 hours. Cells were then stimulatedwith commercially available VEGF121a or VEGF165b (R&DSystems), VEGF121a-TMR or
VEGF165b-TMR (Promega Corporation, USA) at 0.3nM, 3nM or 30nM (in 0.1% serum/medium), or positive control 3nM VEGF165a
(R&D Systems). Following 48 hour stimulation at 37C/5% CO2, cells were washed with 100ml/well PBS, fixed with 3% PFA/PBS
(20minutes, room temperature ) and nuclei stained with 2mg/ml H33342 (15minutes, RT). Nuclei were imaged using an ImageXpress
Micro widefield platereader (Molecular Devices, USA) with a 4x objective using a DAPI filter (4 sites per well, 25ms exposure time).e3 Cell Chemical Biology 25, 1–11.e1–e5, October 18, 2018
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HEKT293 cells stably expressing full-length wild-type VEGFR2, NRP1 or NRP1 Y297A, tagged on the N-terminus with the 19kDa
luciferase NanoLuc, were seeded 24 hours prior to experimentation at 35,000 cells/well on white 96-well clear bottomed plates
(Greiner Bio-One, 655089) pre-coated with poly-D-lysine (0.01mg/ml in PBS), and incubated at 37C/5% CO2. Having identified a
natural polymorphism (V297I) in the NanoLuc-VEGFR2 construct used previously (Kilpatrick et al., 2017), experiments performed
with VEGF165a-TMR verified no distinction from wild type VEGFR2 (Figures 1 and 3). Medium was replaced with Hank’s buffered sa-
line solution (HBSS) containing 0.1% BSA. For full displacement experiments, cells were co-incubated with increasing concentra-
tions of unlabelled ligand (R&D Systems) or vehicle (HBSS/0.1% BSA), as well as fixed concentrations of fluorescently labelled
VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR in duplicate wells (0.25nM, 0.5nM, 1nM, 2nM, 3nM). Additional displacement ex-
periments incubated NanoLuc-VEGFR2 or NanoLuc-NRP1 cells with 3nM VEGF-TMR in the presence and absence of 30nM
competing unlabelled VEGF. For saturation experiments, increasing concentrations of VEGF165a–TMR, VEGF165b-TMR or
VEGF121a-TMR were added in the presence or absence of a high concentration of corresponding unlabelled ligand (100nM,
100-fold greater than the estimated KD value). Following 60min stimulation in the dark at 37C, the NanoLuc substrate furimazine
(final concentration 10mM) was added to each well and equilibrated for 5 minutes to enable NanoLuc-mediated furimazine oxidation
and resulting bioluminescence emission. Emissions were recorded using the PHERAstar FS platereader (BMG Labtech) using filters
measuring NanoLuc emissions at 450nm (30nm bandpass), then TMR emissions using a longpass filter at 550nm for NanoLuc-
VEGFR2 cells or 610nm for cells expressing wild type or mutant NanoLuc-NRP1. BRET ratios were calculated as fluorescence
over luminescence emissions. NanoBRET kinetic experiments were performed at 37C throughout and required furimazine pre-treat-
ment 5 minutes prior to addition of VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR (1nM to 20nM). BRET ratios were then calcu-
lated every 30 seconds for up to 120 minutes.
Live Cell Confocal Imaging
HEKT293 cells stably expressing HaloTag-VEGFR2, HaloTag-NRP1 or HaloTag-NRP1 Y297A were seeded 48 hours prior to imaging
at 20,000 cells/well in 8-well plates (Nunc Lab-Tek, Thermo Fisher Scientific) pre-coated with poly-D-lysine (0.01mg/ml in PBS), then
replaced with serum free DMEM following 24 hours. Cells were treated with 0.5mMmembrane impermeant HaloTag Alexa Fluor 488
substrate (Promega Corporation, USA) in HBSS/0.1%BSA for 30min (37C). Cells were thenwashed twice and replacedwith HBSS/
0.1% BSA prior to incubation with 10nM VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR in the dark at 37
C. Cells were imaged
live using an LSM710 confocal microscope fitted with a 63x Pan Apochromat oil objective (1.4NA) using Argon488 and Argon 546
laser excitation (3% power), a long pass 540 filter and a pin hole diameter of 1 Airy unit. All images were taken at 1024x1024 pixels
per frame with 8 averages.
Fluorescence Correlation Spectroscopy (FCS)
Solution based FCS measurements were performed in Nunc LabTek 8-well chambered coverglasses (Thermo-Fisher Scientific, UK)
using a LSM510 NLO Confocor3 microscope equipped with a c-Apochromat 40/1.2NA water immersion objective (Zeiss, Germany).
The confocal volume was placed 200mm in solution above the surface of the coverglass. Calibration of beam paths was performed
using 20nM Rhodamine 6G (Diffusion coefficient (D) = 2.8 10-10 m2/s; Sigma Aldrich, UK) in high performance liquid chromatography
grade water (Chromasolv; Sigma Aldrich) with 488nm and 561nm laser lines using 10x10sec reads. A range of VEGF165b-TMR or
VEGF121a-TMR (2-10nM) solutions were prepared in HBSS/0.1% BSA in the presence or absence of 10mM DTT. DTT containing
ligand solutions were preincubated for 30min. FCS recordings were collected with 2 sets of 10x10secs reads using 561nm laser exci-
tation (20% power; AOTF set to 10; equivalent to 0.39kW/cm2) with fluorescence emissions collected using a long pass 580
(LP580) filter.
Immunofluorescence Labelling
For confocal imaging (Figure S3), HUVECs, wild type HEKT293T cells or HEK293T cells expressing NanoLuc-VEGFR2 or NanoLuc-
NRP1 were seeded onto poly-D-lysine coated high resolution coverslips (Zeiss, Germany; 18mmx18mm, 1.5H) at 300,000 cells/well
and grown in 6 well culture plates 24 hours prior to experimentation. On the day of the assay, coverslips were transferred to humid-
ified wells lined with parafilm and PBS to avoid dryness and washed 3x5min with PBS. Cells were fixed with 3% paraformaldehyde
(PFA)/PBS for 20min at room temperature (RT), washed (3x5min PBS) and incubated with 3% BSA/1% glycine/PBS to reduce
non-specific binding (30mins, RT). After washing, cells were blocked with 4% chick serum or donkey serum for VEGFR2 and
NRP1 staining respectively (PBS, 30min, RT). This was then replacedwith primary antibody diluted 1:200 in 4% serum/PBS and incu-
bated overnight at 4C (anti-VEGFR1 mAb produced in mice, Sigma V4762; anti-VEGFR2 mAb (mouse), Sigma V9134; anti-NRP1
goat pAb Santa Cruz 7239). The following day, cells were washed and incubated in the dark with secondary antibody diluted
1:500 in 4% serum/PBS for 1 hour at room temperature (VEGFR1 and VEGFR2 chick anti-mouse AlexaFluor488, Invitrogen
A21463; NRP1 donkey anti-goat AlexaFluor546, Invitrogen A11056). Coverslips were washed, mounted onto slides using ProLong
Diamond (Thermo Fisher Scientific), sealed and stored at 4C. Coverslips were imaged using a Confocal Zeiss LSM880 fitted with a
63x Pan Apochromat oil objective (1.4NA) using Argon488 or DPSS561 laser excitation at 2% laser power with a pinhole diameter of 1
Airy unit.
To quantify relative receptor expression (Figure S4), HUVECs, wild type HEK293T cells or HEK293T cells expressing NanoLuc-
and HaloTag- labelled VEGFR2 or NRP1 were seeded at 25,000 cells/well in black 96-well plates pre-coated with poly-D-lysineCell Chemical Biology 25, 1–11.e1–e5, October 18, 2018 e4
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fluorescence staining protocol as above in 96-well plates with VEGFR2 mouse mAb (Sigma V9134) and NRP1 goat pAb (Santa Cruz
7239). Having labelled with respective secondary antibodies, cells were washed with PBS, nuclei were stained with 2mg/ml H33342
(15 minutes, RT), washed and stored in PBS at 4C. Cells were imaged using an ImageXpress Micro widefield platereader with a 20x
objective at 4 sites per well, with a FITC or TRITC filter for VEGFR2 or NRP1 respectively (500ms exposure time) and a DAPI filter
imaging nuclei (25ms exposure time).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data Analysis
All data are presented as mean ± S.E.M. and were analysed using GraphPad Prism 7.02 (San Diego, CA, USA). Equilibrium binding
and functional assays were analysed as described in Kilpatrick et al. (2017). A power calculation was performed to confirm sample
number for statistical comparisons of pKi values obtained with different fluorescent ligands. This was done on the basis of 5 separate
experiments with the anticipated standard deviation obtained in similar experiments and a calculation of the statistical power to
detect a significant change of pKi of 0.3 log units. This yielded a power of 0.99, i.e. there was a 99% chance of detecting a significant
change in pKi value of 0.3 log units. Statistical analyses using one-way ANOVA are described in the corresponding figure legends or
within the text. Significance was defined as p<0.05.
High Content Imaging
Images obtained with the ImageXpress Micro widefield platereader at 4 sites per well were quantified using MetaXpress 2.0 (Molec-
ular Devices, USA). Nuclei were quantified with diameter 5-25mmand 100 graylevel intensity above background. VEGFR2 phosphor-
ylation was quantified (Figures 1D and 1E) using a granularity algorithm, granules were defined as 6-12mm diameter with a graylevel
intensity of 50 above background. Granularity was quantified per cell, baseline-corrected to non-specific binding (secondary anti-
body only) and normalised to cediranib-treated wells (0%) and response to 30nM VEGF165a (100%). Quantifying relative receptor
expression (Figure S4) using a multiwavelength cell scoring algorithm, regions were defined as 2-15mm in size. Due to distinctions
in secondary antibodies, VEGFR2 (FITC) was defined as intensity over 200 graylevels and NRP1 (TRITC) over 50 graylevels. Fluores-
cence was quantified as integrated intensity per cell and baseline-corrected per experiment to non-specific fluorescence (secondary
antibody only).
FCS Autocorrelation Analysis
Autocorrelation analysis was performed using Zen 2010 software (Zeiss, Germany) with all traces fit using a single one component,
free 3D Brownian diffusion model, with a pre-exponential included to account for the triplet state of the fluorophore.
DATA AND SOFTWARE AVAILABILITY
GraphPad Prism 7.02 (San Diego, CA, USA) was used to analyse the quantified data and produce the graphs. Zen 2010 (Zeiss; Ger-
many) was used to perform autocorrelation analysis for FCS.MetaXpress 2.0 (Molecular Devices, USA) was used to quantify VEGFR2
phosphorylation and receptor expression labelled with immunofluorescence following high content imaging on the widefield
platereader.e5 Cell Chemical Biology 25, 1–11.e1–e5, October 18, 2018
